Clinicopathological Significance and Prognostic Role of Tumor-infiltrating Lymphocytes in Colorectal Cancer
Overview
Oncology
Authors
Affiliations
Purpose: This study aimed to elucidate the clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
Methods: The immunohistochemistry of CD3 and CD8 was performed on 265 human colorectal cancer tissues to investigate the tumor-infiltrating lymphocytes using Immunoscore. The correlation between Immunoscore and clinicopathological characteristics, including survival rates, was elucidated. In addition, the impact of tumor-infiltrating lymphocytes on programmed death-ligand 1 (PD-L1) protein expression was evaluated through immunohistochemistry.
Results: Of the 265 colorectal cancer tissues, 40.8% had high Immunoscore, while 59.2% had low Immunoscore. A high Immunoscore was significantly correlated with favorable tumor behaviors, including lower rates of vascular, lymphatic, and perineural invasion; lymph node metastasis; and distant metastasis. PD-L1 expressions of tumor and immune cells were significantly higher in patients with high Immunoscore than in those with low Immunoscore. In addition, colorectal cancer tissues with high CD8-positive lymphocytes showed higher PD-L1 expressions of tumor and immune cells than colorectal cancer tissues with low CD8-positive lymphocytes. There was a significant correlation between high Immunoscore and better overall survival. However, there was no significant difference in survival rate according to PD-L1 expressions of tumor and immune cells in high and low Immunoscore subgroups.
Conclusions: Taken together, our results showed that high tumor-infiltrating lymphocytes were significantly correlated with favorable tumor behaviors and better survival. In addition, there was a significant correlation between PD-L1 expression and tumor-infiltrating lymphocytes.
Isah Tsamiya R, Nafi S, Che Jalil N, Mat Zin A Malays J Med Sci. 2024; 31(1):200-211.
PMID: 38456100 PMC: 10917589. DOI: 10.21315/mjms2024.31.1.17.
Franzen A, Boulifa A, Radecke C, Stintzing S, Raftery M, Pecher G Cancers (Basel). 2024; 16(2).
PMID: 38254876 PMC: 10814835. DOI: 10.3390/cancers16020388.
Pyo J, Choi J, Kim N, Min K, Kang D J Clin Med. 2024; 13(1).
PMID: 38202141 PMC: 10779795. DOI: 10.3390/jcm13010134.
Gawesh Z, Ibrahim E, ElKalla H, Awad A, Mohamed M Asian Pac J Cancer Prev. 2023; 24(12):4309-4319.
PMID: 38156868 PMC: 10909113. DOI: 10.31557/APJCP.2023.24.12.4309.
Saito-Koyama R, Tamai K, Yasuda J, Okamura Y, Yamazaki Y, Inoue C Virchows Arch. 2023; 484(4):609-620.
PMID: 37171482 DOI: 10.1007/s00428-023-03548-z.